Xenoport, Inc. (NASDAQ:XNPT): Leerink believes that preliminary results from XenoPort’s Phase I trial testing four different oral formulations of XP23829 is encouraging. The firm keeps its Outperform rating and raised its price target to $15 from $13 on the stock.
Kaydon Corporation (NYSE:KDN): According to William Blair, investors will probably look past Kaydon’s Q3 charge since most of the charge is not cash. The firm thinks that the announcements lift an overhang on the stock, and it reiterates its Market Perform rating on the stock.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Cabot Oil & Gas Corporation (NYSE:COG) price target was increased by Canaccord based on incremental Marcellus growth that was driven by system optimization. Shares have a Buy rating.
Facebook, Inc. (NASDAQ:FB): Jefferies stated that it has growing optimism regarding Facebook’s long-term prospects as the company clarifies its monetization strategy. The firm believes that Facebook Exchange is the company’s most interesting monetization lever since it thinks that ads sold through the platform could call for higher rates than the current ads they displace. Jefferies also believes that growing companies like king.com should limit the impact of Zynga’s (NASDAQ:ZNGA) negative preannouncement. The firm maintains its Buy rating and $30 price target on the stock.
Pier 1 Imports Inc. (NYSE:PIR) investment story is believed by Oppenheimer to be starting to take shape although shares have risen 36 percent since December. The firm keeps its Outperform rating and increases its price target on the stock.